Potential of mesenchymal stem cells in modulating oxidative stress in management of lung diseases

The current therapies for oxidative stress-induced lung diseases are majorly based on the reduction of airway obstruction and improved exacerbations. However, none of the available treatments have been proven to avoid disease progression or reduce mortality. In this context, mesenchymal stem cell (MSC) therapy has become a strong contender for better therapeutic strategies for several pulmonary diseases. MSCs can be readily harvested from various tissues and efficiently propagated and possess strong immunomodulatory/suppressive properties. Animal studies have shown encouraging outcomes with MSC therapy for various lung disorders, like COPD and emphysema. These studies have inspired research groups to understand the mechanisms by which MSCs may bring about their beneficial effects upon transplantation; however, clinical trials have not been as successful. This chapter summarizes and highlights the various aspects of MSC therapy in cellular, preclinical, and clinical settings.